Syndax宣布四篇Revuforj® (Revumenib)摘要获选2026年美国临床肿瘤学会年会,包括移植后数据口头报告

美股速递
May 22

Syndax Pharmaceuticals, Inc. 宣布,其四篇关于Revuforj® (Revumenib)的研究摘要已被2026年美国临床肿瘤学会(ASCO)年会接受,其中包含一项移植后数据的口头报告。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10